Progressive Fibrotic Interstitial Lung Disease
Conditions
Brief summary
Rate of decline of FVC (in mL) over a period of 26 weeks
Detailed description
Absolute decline in percent predicted forced vital capacity (%FVC) over 13 and 26 weeks, All-cause mortality., Chance in Vas of dyspnea, All-cause non-elective hospitalizations, Respiratory-related mortality, Acute exacerbations (as evaluated by the investigator), Changes in quality of life, assessed by the EQ-5D, Amount and type of adverse events., Changes in quality of life, assessed by the SGRQ-I and K-BILD total score. (Danish and UK sites only)
Interventions
DRUGSenicapoc
DRUGPLACEBO
Sponsors
Lillebaelt Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Absolute decline in percent predicted forced vital capacity (%FVC) over 13 and 26 weeks, All-cause mortality., Chance in Vas of dyspnea, All-cause non-elective hospitalizations, Respiratory-related mortality, Acute exacerbations (as evaluated by the investigator), Changes in quality of life, assessed by the EQ-5D, Amount and type of adverse events., Changes in quality of life, assessed by the SGRQ-I and K-BILD total score. (Danish and UK sites only) | — |
Primary
| Measure | Time frame |
|---|---|
| Rate of decline of FVC (in mL) over a period of 26 weeks | — |
Countries
Denmark, Estonia
Outcome results
None listed